This is part 4 of an interview. Watch part 1, part 2, and part 3.

Objective response rate was 35% (3 CR, 3 PR), with most patients demonstrating primary progression despite meeting ...

New KRAS-targeting drug for metastatic pancreatic cancer nearly doubles second-line survival; expert explains impact, side effects, next trials.

Chromosome 13q linkage promotes RB1 hemizygosity during BRCA2 LOH, lowering the ‘two-hit’ barrier and predisposing to ...

Betts, MD, discusses how PTCy and tacrolimus protocols, as well as using younger donors, contributes to higher survival rates ...

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks ...

Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.

MCED screening and broader genetic testing push community oncology toward prevention—learn how practices adapt workflows, ...

Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...

In an interview with Targeted OncologyTM, Ranjit Goudar, MD, of Virginia Oncology Associates, discusses the ongoing barriers ...

Dr Joyce Ohm discusses the ethical questions raised by genome sequencing, from data ownership to reporting mutations of unknown significance. This is part 3 of an interview. Watch part 1 and part 2.

Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...